Compounds > thiotepa
Page last updated: 2024-11-05

thiotepa and Germinoblastoma

thiotepa has been researched along with Germinoblastoma in 69 studies

Thiotepa: A very toxic alkylating antineoplastic agent also used as an insect sterilant. It causes skin, gastrointestinal, CNS, and bone marrow damage. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), thiotepa may reasonably be anticipated to be a carcinogen (Merck Index, 11th ed).

Research Excerpts

ExcerptRelevanceReference
"Thiotepa, busulfan and cyclophosphamide-based intensive chemotherapy is an effective treatment for refractory and recurrent primary central nervous system lymphoma in chemosensitive patients up to 65 years of age."9.16Intensive chemotherapy with thiotepa, busulfan and cyclophosphamide and hematopoietic stem cell rescue in relapsed or refractory primary central nervous system lymphoma and intraocular lymphoma: a retrospective study of 79 cases. ( Bouabdallah, K; Choquet, S; Damaj, G; Delgadillo, D; Dupriez, B; Fourme, E; Ghesquières, H; Gonzalez, A; Hoang-Xuan, K; Houillier, C; Leblond, V; Soussain, C; Taillandier, L; Vargaftig, J, 2012)
"The combination of high doses of methotrexate (MTX) and cytarabine (araC) is the standard chemotherapy for patients with primary CNS lymphoma (PCNSL)."9.15Clinical relevance of the dose of cytarabine in the upfront treatment of primary CNS lymphomas with methotrexate-cytarabine combination. ( Corazzelli, G; Fava, S; Ferreri, AJ; Foppoli, M; Franzin, A; Licata, G; Paolini, R; Politi, LS; Ponzoni, M; Reni, M; Stelitano, C; Zaja, F; Zucca, E, 2011)
"We investigated the efficacy and safety of tandem high-dose methotrexate (HD-MTX) induction followed by high-dose busulfan/thiotepa (HD-BuTT) with autologous peripheral blood stem-cell transplantation (aPBSCT) and response-adapted whole-brain radiation therapy (WBRT) in patients with newly diagnosed primary central nervous system lymphoma."9.12Primary central nervous system lymphoma treated with high-dose methotrexate, high-dose busulfan/thiotepa, autologous stem-cell transplantation and response-adapted whole-brain radiotherapy: results of the multicenter Ostdeutsche Studiengruppe Hamato-Onkol ( Al-Ali, HK; Dölken, G; Haas, A; Helke, K; Herbst, R; Hirt, C; Kiefer, T; Krüger, WH; Lotze, C; Montemurro, M; Niederwieser, D; Schüler, F; Schwenke, M; Theilig, A; Wolf, HH, 2007)
"Thirty-four adults with malignant lymphoma at high-risk for relapse were treated on a Phase I-II study of high-dose thiotepa (THIO), busulfan (BU) and cyclophosphamide (CYC) with autologous marrow or peripheral blood stem cell support."9.08A phase I-II study of high-dose thiotepa, busulfan and cyclophosphamide as a preparative regimen for autologous transplantation for malignant lymphoma. ( Diener, K; Dimopoulos, M; Giralt, S; Hagemeister, F; Ippoliti, C; Khouri, I; Mehra, R; Nath, R; Przepiorka, D; Samuels, B, 1995)
"Thiotepa-based conditioning followed by HSCT may be effective in most CNS lymphoma patients, with a manageable toxicity profile."8.90Effectiveness and safety of thiotepa as conditioning treatment prior to stem cell transplant in patients with central nervous system lymphoma. ( Bredeson, C; Fergusson, D; Kokolo, MB; O'Neill, J; Stewart, D; Tay, J; Tinmouth, AT, 2014)
"In primary central nervous system lymphoma, two-year progression-free survival rates of up to 63 percent have been reported for first-line autologous stem cell transplantation after conditioning with the thiotepa busulfan cyclophosphamide regimen."8.31Thiotepa, Busulfan, Cyclophosphamide: Effective but Toxic Conditioning Regimen Prior to Autologous Hematopoietic Stem Cell Transplantation in Central Nervous System Lymphoma. ( Bérengère, G; Bruno, R; Delphine, L; Jean-Pierre, M; Magalie, J; Patrick, V; Pierre, M; Pierre-Edouard, D, 2023)
"A retrospective analysis was performed of 48 consecutive patients who had undergone HDC/ASCT with TBC (thiotepa, busulfan, cyclophosphamide) conditioning for PCNSL (27 patients), secondary CNS lymphoma (SCNSL) (8 patients), or relapsed disease with CNS involvement (13 patients) from July 2006 to December 2017."7.96Durable Survival Outcomes in Primary and Secondary Central Nervous System Lymphoma After High-dose Chemotherapy and Autologous Stem Cell Transplantation Using a Thiotepa, Busulfan, and Cyclophosphamide Conditioning Regimen. ( Chute, J; de Vos, S; Eradat, HA; Gaut, D; Grotts, J; Kimaiyo, DK; Romero, T; Schiller, G; Timmerman, J; Young, PA, 2020)
"We investigated the incidence of viral, fungal, bacterial, and parasitic infections observed in 57 patients with central nervous system lymphoma after thiotepa, busulfan, and cyclophosphamide-conditioned autologous stem cell transplantation (TBC-ASCT) and 79 patients with systemic non-Hodgkin lymphoma after traditional carmustine, etoposide, cytarabine, and melphalan-conditioned ASCT (BEAM-ASCT)."7.88Distinctive Infectious Complications in Patients with Central Nervous System Lymphoma Undergoing Thiotepa, Busulfan, and Cyclophosphamide-conditioned Autologous Stem Cell Transplantation. ( Bhatia, A; Chung, HH; DeAngelis, LM; Giralt, SA; Littmann, ER; Maloy, M; Morjaria, SM; Sauter, CS; Scordo, M; Taur, Y, 2018)
"High-dose therapy and autologous stem cell transplantation (ASCT) with thiotepa, busulfan, and cyclophosphamide (TBC) conditioning has emerged as an effective postinduction treatment strategy for patients with primary central nervous system lymphoma (PCNSL) or secondary central nervous system lymphoma (SCNSL), but it is associated with considerable toxicity and transplantation-related mortality (TRM) in the modern era."7.85A Comprehensive Assessment of Toxicities in Patients with Central Nervous System Lymphoma Undergoing Autologous Stem Cell Transplantation Using Thiotepa, Busulfan, and Cyclophosphamide Conditioning. ( Bhatt, V; Dahi, PB; DeAngelis, LM; Giralt, SA; Hsu, M; Matasar, MJ; Moskowitz, CH; Omuro, AM; Sauter, CS; Scordo, M, 2017)
"Clinical information about thiotepa-based autologous stem cell transplantation (auto-SCT) outside the primary central nervous system lymphoma (PCNSL) field is sparse."7.83Thiotepa-based high-dose therapy for autologous stem cell transplantation in lymphoma: a retrospective study from the EBMT. ( Amorim, S; Bouabdallah, R; Boumendil, A; Choquet, S; de Rosa, G; Delmer, A; Dreger, P; Faber, E; Facchini, L; Falzetti, F; Ferrara, F; Finel, H; Finke, J; Kobbe, G; Nicolas-Virelizier, E; Salles, G; Sayer, H; Scime, R; Sellner, L; Sureda, A; Vallisa, D; Yakoub-Agha, I; Zuffa, E, 2016)
"The aim of this study was to evaluate the efficacy and toxicity of two chemotherapy regimens based on platinum and cytarabine in association with etoposide and methylprednisolone (ESHAP) or with dexamethasone (DHAP) with or without Rituximab (± R) in patients with refractory or a relapsed Primary Central Nervous System Lymphoma (PCNSL)."7.77Platine and cytarabine-based salvage treatment for primary central nervous system lymphoma. ( Choquet, S; del Rio, MS; Fourme, E; Glaisner, S; Hoang-Xuan, K; Janvier, M; Soussain, C, 2011)
"The purpose of this evaluation was to investigate the efficacy of high-dose chemotherapy with thiotepa, melphalan, and carboplatin (TMCb), and of autologous peripheral blood stem cell (PBSC) infusion in patients with aggressive non-Hodgkin's lymphoma (NHL) or Hodgkin's disease (HD)."7.72High-dose thiotepa, melphalan and carboplatin (TMCb) followed by autologous peripheral blood stem cell transplantation in patients with lymphoma -- a retrospective evaluation. ( Akan, H; Arat, M; Arslan, O; Ayli, M; Buyukberber, S; Demirer, T; Fen, T; Gurman, G; Ilhan, O; Ozcan, M, 2004)
"We retrospectively analyzed 132 malignant lymphoma patients who underwent ASCT."5.43High pre-transplant serum ferritin and busulfan-thiotepa conditioning regimen as risk factors for hepatic sinusoidal obstructive syndrome after autologous stem cell transplantation in patients with malignant lymphoma. ( Cheong, JW; Hwang, DY; Jang, JE; Kim, JS; Kim, SJ; Kim, Y; Lee, JY; Min, YH; Yang, WI, 2016)
"Thiotepa, busulfan and cyclophosphamide-based intensive chemotherapy is an effective treatment for refractory and recurrent primary central nervous system lymphoma in chemosensitive patients up to 65 years of age."5.16Intensive chemotherapy with thiotepa, busulfan and cyclophosphamide and hematopoietic stem cell rescue in relapsed or refractory primary central nervous system lymphoma and intraocular lymphoma: a retrospective study of 79 cases. ( Bouabdallah, K; Choquet, S; Damaj, G; Delgadillo, D; Dupriez, B; Fourme, E; Ghesquières, H; Gonzalez, A; Hoang-Xuan, K; Houillier, C; Leblond, V; Soussain, C; Taillandier, L; Vargaftig, J, 2012)
"The combination of high doses of methotrexate (MTX) and cytarabine (araC) is the standard chemotherapy for patients with primary CNS lymphoma (PCNSL)."5.15Clinical relevance of the dose of cytarabine in the upfront treatment of primary CNS lymphomas with methotrexate-cytarabine combination. ( Corazzelli, G; Fava, S; Ferreri, AJ; Foppoli, M; Franzin, A; Licata, G; Paolini, R; Politi, LS; Ponzoni, M; Reni, M; Stelitano, C; Zaja, F; Zucca, E, 2011)
"We investigated the efficacy and safety of tandem high-dose methotrexate (HD-MTX) induction followed by high-dose busulfan/thiotepa (HD-BuTT) with autologous peripheral blood stem-cell transplantation (aPBSCT) and response-adapted whole-brain radiation therapy (WBRT) in patients with newly diagnosed primary central nervous system lymphoma."5.12Primary central nervous system lymphoma treated with high-dose methotrexate, high-dose busulfan/thiotepa, autologous stem-cell transplantation and response-adapted whole-brain radiotherapy: results of the multicenter Ostdeutsche Studiengruppe Hamato-Onkol ( Al-Ali, HK; Dölken, G; Haas, A; Helke, K; Herbst, R; Hirt, C; Kiefer, T; Krüger, WH; Lotze, C; Montemurro, M; Niederwieser, D; Schüler, F; Schwenke, M; Theilig, A; Wolf, HH, 2007)
"Thirty-four adults with malignant lymphoma at high-risk for relapse were treated on a Phase I-II study of high-dose thiotepa (THIO), busulfan (BU) and cyclophosphamide (CYC) with autologous marrow or peripheral blood stem cell support."5.08A phase I-II study of high-dose thiotepa, busulfan and cyclophosphamide as a preparative regimen for autologous transplantation for malignant lymphoma. ( Diener, K; Dimopoulos, M; Giralt, S; Hagemeister, F; Ippoliti, C; Khouri, I; Mehra, R; Nath, R; Przepiorka, D; Samuels, B, 1995)
"Thiotepa-based conditioning followed by HSCT may be effective in most CNS lymphoma patients, with a manageable toxicity profile."4.90Effectiveness and safety of thiotepa as conditioning treatment prior to stem cell transplant in patients with central nervous system lymphoma. ( Bredeson, C; Fergusson, D; Kokolo, MB; O'Neill, J; Stewart, D; Tay, J; Tinmouth, AT, 2014)
"In primary central nervous system lymphoma, two-year progression-free survival rates of up to 63 percent have been reported for first-line autologous stem cell transplantation after conditioning with the thiotepa busulfan cyclophosphamide regimen."4.31Thiotepa, Busulfan, Cyclophosphamide: Effective but Toxic Conditioning Regimen Prior to Autologous Hematopoietic Stem Cell Transplantation in Central Nervous System Lymphoma. ( Bérengère, G; Bruno, R; Delphine, L; Jean-Pierre, M; Magalie, J; Patrick, V; Pierre, M; Pierre-Edouard, D, 2023)
"A retrospective analysis was performed of 48 consecutive patients who had undergone HDC/ASCT with TBC (thiotepa, busulfan, cyclophosphamide) conditioning for PCNSL (27 patients), secondary CNS lymphoma (SCNSL) (8 patients), or relapsed disease with CNS involvement (13 patients) from July 2006 to December 2017."3.96Durable Survival Outcomes in Primary and Secondary Central Nervous System Lymphoma After High-dose Chemotherapy and Autologous Stem Cell Transplantation Using a Thiotepa, Busulfan, and Cyclophosphamide Conditioning Regimen. ( Chute, J; de Vos, S; Eradat, HA; Gaut, D; Grotts, J; Kimaiyo, DK; Romero, T; Schiller, G; Timmerman, J; Young, PA, 2020)
"Autologous stem cell transplantation (ASCT) with high-dose thiotepa and busulfan is a treatment option for patients with central nervous system (CNS) lymphoma."3.96Secondary failure of platelet recovery in patients treated with high-dose thiotepa and busulfan followed by autologous stem cell transplantation. ( Aiba, A; Hishizawa, M; Kitano, T; Kondo, T; Nishikori, M; Shimazu, Y; Shindo, T; Takaori-Kondo, A; Wada, F; Watanabe, M, 2020)
"We investigated the incidence of viral, fungal, bacterial, and parasitic infections observed in 57 patients with central nervous system lymphoma after thiotepa, busulfan, and cyclophosphamide-conditioned autologous stem cell transplantation (TBC-ASCT) and 79 patients with systemic non-Hodgkin lymphoma after traditional carmustine, etoposide, cytarabine, and melphalan-conditioned ASCT (BEAM-ASCT)."3.88Distinctive Infectious Complications in Patients with Central Nervous System Lymphoma Undergoing Thiotepa, Busulfan, and Cyclophosphamide-conditioned Autologous Stem Cell Transplantation. ( Bhatia, A; Chung, HH; DeAngelis, LM; Giralt, SA; Littmann, ER; Maloy, M; Morjaria, SM; Sauter, CS; Scordo, M; Taur, Y, 2018)
"High-dose therapy and autologous stem cell transplantation (ASCT) with thiotepa, busulfan, and cyclophosphamide (TBC) conditioning has emerged as an effective postinduction treatment strategy for patients with primary central nervous system lymphoma (PCNSL) or secondary central nervous system lymphoma (SCNSL), but it is associated with considerable toxicity and transplantation-related mortality (TRM) in the modern era."3.85A Comprehensive Assessment of Toxicities in Patients with Central Nervous System Lymphoma Undergoing Autologous Stem Cell Transplantation Using Thiotepa, Busulfan, and Cyclophosphamide Conditioning. ( Bhatt, V; Dahi, PB; DeAngelis, LM; Giralt, SA; Hsu, M; Matasar, MJ; Moskowitz, CH; Omuro, AM; Sauter, CS; Scordo, M, 2017)
"Clinical information about thiotepa-based autologous stem cell transplantation (auto-SCT) outside the primary central nervous system lymphoma (PCNSL) field is sparse."3.83Thiotepa-based high-dose therapy for autologous stem cell transplantation in lymphoma: a retrospective study from the EBMT. ( Amorim, S; Bouabdallah, R; Boumendil, A; Choquet, S; de Rosa, G; Delmer, A; Dreger, P; Faber, E; Facchini, L; Falzetti, F; Ferrara, F; Finel, H; Finke, J; Kobbe, G; Nicolas-Virelizier, E; Salles, G; Sayer, H; Scime, R; Sellner, L; Sureda, A; Vallisa, D; Yakoub-Agha, I; Zuffa, E, 2016)
"The aim of this study was to evaluate the efficacy and toxicity of two chemotherapy regimens based on platinum and cytarabine in association with etoposide and methylprednisolone (ESHAP) or with dexamethasone (DHAP) with or without Rituximab (± R) in patients with refractory or a relapsed Primary Central Nervous System Lymphoma (PCNSL)."3.77Platine and cytarabine-based salvage treatment for primary central nervous system lymphoma. ( Choquet, S; del Rio, MS; Fourme, E; Glaisner, S; Hoang-Xuan, K; Janvier, M; Soussain, C, 2011)
"The purpose of this evaluation was to investigate the efficacy of high-dose chemotherapy with thiotepa, melphalan, and carboplatin (TMCb), and of autologous peripheral blood stem cell (PBSC) infusion in patients with aggressive non-Hodgkin's lymphoma (NHL) or Hodgkin's disease (HD)."3.72High-dose thiotepa, melphalan and carboplatin (TMCb) followed by autologous peripheral blood stem cell transplantation in patients with lymphoma -- a retrospective evaluation. ( Akan, H; Arat, M; Arslan, O; Ayli, M; Buyukberber, S; Demirer, T; Fen, T; Gurman, G; Ilhan, O; Ozcan, M, 2004)
"Diagnoses were AML (n=18), ALL (n=3), multiple myeloma (n=11), lymphoma (n=16) and CML (n=1)."2.73A fludarabine, thiotepa reduced toxicity conditioning regimen designed specifically for allogeneic second haematopoietic cell transplantation after failure of previous autologous or allogeneic transplantation. ( Bertz, H; Finke, J; Grüllich, C; Müller, CI; Spyridonidis, A, 2008)
" We determined the pharmacokinetics of thioTEPA and its metabolite TEPA during first-dose infusion of thioTEPA 150-250 mg/m2 given daily for 3 days in combination with busulfan and cyclophosphamide, and evaluated the results for correlations with toxicity and dosing strategies."2.68Dosing of thioTEPA for myeloablative therapy. ( Dimopoulos, M; Estrov, Z; Ippoliti, C; Madden, T; Przepiorka, D, 1995)
"Leptomeningeal carcinomatosis is defined as malignant infiltration of the pia matter and arachnoid membrane."2.43Management of leptomeningeal malignancy. ( Pavlidis, N; Pentheroudakis, G, 2005)
" CNS relapse and neurotoxicity in patients with acute lymphoblastic leukaemia, especially younger children, may be reduced by using age-related dosing of intrathecal MTX and Ara-C."2.41Intrathecal chemotherapy with antineoplastic agents in children. ( Biagi, E; Conter, V; Lazzareschi, I; Milani, M; Riccardi, R; Ruggiero, A; Sparano, P, 2001)
"However, survivors of brain tumors and any survivor who received high-dose neurotoxic treatment reported the lowest rates of achieving milestones of psychosexual development, whereas sexual and relationship status satisfaction were found to be related to relationship status."1.46Psychosexual development and satisfaction in long-term survivors of childhood cancer: Neurotoxic treatment intensity as a risk indicator. ( Bajwa, RPS; Gerhardt, CA; Hagedoorn, M; Keim, MC; Lehmann, V; Olshefski, RS; Tuinman, MA; Winning, AM, 2017)
"We retrospectively analyzed 132 malignant lymphoma patients who underwent ASCT."1.43High pre-transplant serum ferritin and busulfan-thiotepa conditioning regimen as risk factors for hepatic sinusoidal obstructive syndrome after autologous stem cell transplantation in patients with malignant lymphoma. ( Cheong, JW; Hwang, DY; Jang, JE; Kim, JS; Kim, SJ; Kim, Y; Lee, JY; Min, YH; Yang, WI, 2016)
"Among the causes of IRM, bacterial infections and IFIs were more common in sCBT (15% vs."1.42Severe infections after single umbilical cord blood transplantation in adults with or without the co-infusion of CD34+ cells from a third-party donor: results of a multicenter study from the Grupo Español de Trasplante Hematopoyético (GETH). ( Barba, P; Bautista, G; Cabrera, JR; Duarte, R; Esquirol, A; Fores, R; García, I; García-Marco, JA; Heras, I; Marquez-Malaver, FJ; Martino, R; Parody, R; Regidor, C; Rovira, M; Saavedra, S; Sánchez-Ortega, I; Serrano, D; Sierra, J; Vazquez, L, 2015)

Research

Studies (69)

TimeframeStudies, this research(%)All Research%
pre-199020 (28.99)18.7374
1990's11 (15.94)18.2507
2000's8 (11.59)29.6817
2010's19 (27.54)24.3611
2020's11 (15.94)2.80

Authors

AuthorsStudies
Schenone, L1
Houillier, C2
Tanguy, ML1
Choquet, S4
Agbetiafa, K1
Ghesquières, H2
Damaj, G2
Schmitt, A1
Bouabdallah, K2
Ahle, G1
Gressin, R1
Cornillon, J1
Houot, R1
Marolleau, JP1
Fornecker, LM1
Chinot, O1
Peyrade, F1
Bouabdallah, R2
Moluçon-Chabrot, C1
Gyan, E1
Chauchet, A1
Casasnovas, O1
Oberic, L1
Delwail, V1
Abraham, J1
Roland, V1
Waultier-Rascalou, A1
Willems, L1
Morschhauser, F1
Fabbro, M1
Ursu, R1
Thieblemont, C1
Jardin, F1
Tempescul, A1
Malaise, D1
Touitou, V1
Nichelli, L1
Le Garff-Tavernier, M1
Plessier, A1
Bourget, P1
Bonmati, C1
Wantz-Mézières, S1
Giordan, Q1
Dorvaux, V1
Charron, C1
Jabeur, W1
Hoang-Xuan, K3
Taillandier, L2
Soussain, C3
Ferreri, AJM3
Cwynarski, K2
Pulczynski, E1
Fox, CP2
Schorb, E3
Celico, C1
Falautano, M1
Nonis, A1
La Rosée, P1
Binder, M1
Fabbri, A1
Ilariucci, F2
Krampera, M1
Roth, A1
Hemmaway, C1
Johnson, PW1
Linton, KM2
Pukrop, T1
Gørløv, JS1
Balzarotti, M2
Hess, G1
Keller, U1
Stilgenbauer, S1
Panse, J1
Tucci, A1
Orsucci, L1
Pisani, F1
Zanni, M1
Krause, SW1
Schmoll, HJ1
Hertenstein, B1
Rummel, M1
Smith, J2
Thurner, L1
Cabras, G1
Pennese, E1
Ponzoni, M2
Deckert, M1
Politi, LS2
Finke, J5
Ferranti, A1
Cozens, K1
Burger, E1
Ielmini, N1
Cavalli, F1
Zucca, E2
Illerhaus, G4
de Pádua Covas Lage, LA1
Araújo Soares, V1
Meneguin, TD1
Culler, HF1
Reichert, CO1
Jacomassi, MD1
Reis, DGC1
Zerbini, MCN1
de Oliveira Costa, R1
Rocha, V1
Pereira, J1
Khwaja, J1
Kirkwood, AA1
Isbell, LK1
Steffanoni, S1
Goradia, H1
Pospiech, L1
Fail, T1
Nicholson, E1
Fletcher, K1
Parsons, KE1
Elmusharaf, N1
Eccersley, L1
Eyre, TA1
Chaganti, S1
Thakrar, N1
Kutilina, A1
Calimeri, T1
Martinez-Calle, N1
El-Sharkawi, D1
Osborne, W1
Suleman, A3
Liu, J3
Hicks, LK3
Drori, AK3
Crump, M3
Kridel, R3
Prica, A3
Berinstein, N3
Delphine, L1
Pierre-Edouard, D1
Bruno, R1
Bérengère, G1
Magalie, J1
Patrick, V1
Jean-Pierre, M1
Pierre, M1
Cohen, YI1
Lebel, E1
Zimran, E1
Shaulov, A1
Stepensky, P1
Grisariu, S1
Avni, B1
Othman, T1
Quan, MA1
Zhang, S1
Gaut, D2
Young, PA2
Mahmood, O1
Abdulhaq, H1
Shieh, K1
Reid, J1
Brem, EA1
Hariharan, N1
Heyman, B1
Tuscano, J1
Kimaiyo, DK1
Grotts, J1
Romero, T1
Chute, J1
Schiller, G1
de Vos, S1
Eradat, HA1
Timmerman, J1
Wada, F1
Nishikori, M1
Hishizawa, M1
Watanabe, M1
Aiba, A1
Kitano, T1
Shimazu, Y1
Shindo, T1
Kondo, T1
Takaori-Kondo, A1
Hill, JM1
Meehan, KR1
DeFilipp, Z1
Li, S1
El-Jawahri, A1
Armand, P1
Nayak, L1
Wang, N1
Batchelor, TT1
Chen, YB1
Rajagopal, R1
Miles, GCP1
Kotecha, RS1
Scordo, M2
Morjaria, SM1
Littmann, ER1
Bhatia, A1
Chung, HH1
Maloy, M1
DeAngelis, LM4
Giralt, SA2
Taur, Y1
Sauter, CS2
Sanders, S1
Chua, N2
Larouche, JF1
Owen, C1
Shafey, M1
Stewart, DA3
Hyung, J1
Hong, JY1
Yoon, DH1
Kim, S1
Park, JS1
Park, CS1
Lee, SW1
Kim, JH1
Ryu, JS1
Huh, J1
Suh, C1
Kokolo, MB1
Fergusson, D1
O'Neill, J1
Tay, J1
Tinmouth, AT1
Stewart, D1
Bredeson, C1
Ferreri, AJ2
Ciceri, F1
Brandes, AA1
Montanari, M1
Spina, M1
Zaja, F2
Stelitano, C2
Bobbio, F1
Corazzelli, G2
Baldini, L1
Reni, M2
Martino, R1
Bautista, G1
Parody, R1
García, I1
Esquirol, A1
Rovira, M1
Cabrera, JR1
Regidor, C1
Fores, R1
García-Marco, JA1
Serrano, D1
Barba, P1
Heras, I1
Marquez-Malaver, FJ1
Sánchez-Ortega, I1
Duarte, R1
Saavedra, S1
Sierra, J1
Vazquez, L1
Oh, DH1
Street, L1
Hwang, DY1
Kim, SJ1
Cheong, JW1
Kim, Y1
Jang, JE1
Lee, JY1
Min, YH1
Yang, WI1
Kim, JS1
van der Weyden, C1
Prince, HM1
Sellner, L1
Boumendil, A1
Finel, H1
de Rosa, G1
Falzetti, F1
Scime, R1
Kobbe, G1
Ferrara, F1
Delmer, A1
Sayer, H1
Amorim, S1
Salles, G1
Yakoub-Agha, I1
Faber, E1
Nicolas-Virelizier, E1
Facchini, L1
Vallisa, D1
Zuffa, E1
Sureda, A1
Dreger, P1
Bhatt, V1
Hsu, M1
Omuro, AM2
Matasar, MJ1
Dahi, PB1
Moskowitz, CH1
Lehmann, V1
Tuinman, MA1
Keim, MC1
Winning, AM1
Olshefski, RS1
Bajwa, RPS1
Hagedoorn, M1
Gerhardt, CA1
Licata, G1
Foppoli, M1
Fava, S1
Paolini, R1
Franzin, A1
del Rio, MS1
Glaisner, S1
Fourme, E2
Janvier, M1
Kasenda, B1
Fritsch, K1
Delgadillo, D1
Dupriez, B1
Vargaftig, J1
Gonzalez, A1
Leblond, V1
Cheng, T1
Forsyth, P1
Chaudhry, A1
Morris, D1
Glück, S1
Russell, JA1
YAMAGUCHI, H1
TERASHITA, N1
TABUCHI, Y1
IKEDA, E1
FUKUI, S1
ONO, S1
YAMADA, H1
KUNI, A1
ROSSOLIMO, OK2
LEPESHKINA, GN1
ZEZZANETO, L1
SOERENSEN, B1
SALIBA, AM1
GRECCHI, R1
VIGI, F1
ARIEL, IM1
RESNICK, MI1
GALEY, D1
HILLER, SA1
LIDAKS, MJ1
ZIDERMANE, AA1
GERMANE, SK1
GRIGALINOVICH, GA1
DAUVARTS, AZ1
KRAVCHENKO, IM1
PRESS, BO1
CHORIN, VA1
GOLDBERG, LE1
STANISLAVSKAYA, MS1
BLUMBERG, NA1
VERTOGRADOVA, TP1
ROSENGERG, LM1
POLANCO, GB1
BLANK, S1
Demirer, T2
Ayli, M1
Fen, T1
Ozcan, M1
Arat, M1
Buyukberber, S1
Arslan, O1
Gurman, G1
Akan, H1
Ilhan, O1
Yahalom, J1
Abrey, LE1
Pentheroudakis, G1
Pavlidis, N1
Marks, R1
Ihorst, G1
Guttenberger, R1
Ostertag, C1
Derigs, G1
Frickhofen, N1
Feuerhake, F1
Volk, B1
Montemurro, M1
Kiefer, T1
Schüler, F1
Al-Ali, HK1
Wolf, HH1
Herbst, R1
Haas, A1
Helke, K1
Theilig, A1
Lotze, C1
Hirt, C1
Niederwieser, D1
Schwenke, M1
Krüger, WH1
Dölken, G1
Grüllich, C1
Bertz, H1
Spyridonidis, A1
Müller, CI1
Lokich, J1
Galbo, C1
Przepiorka, D3
Madden, T1
Ippoliti, C3
Estrov, Z1
Dimopoulos, M2
Nath, R1
Mehra, R2
Hagemeister, F1
Diener, K1
Giralt, S2
Khouri, I1
Samuels, B1
Xu, T1
Sørensen, JB1
Lichtman, SM1
van Beisen, K1
Deisseroth, AB1
Andersson, B1
Luna, M1
Cork, A1
Lee, M1
Freilich, RJ1
Delattre, JY1
Monjour, A1
Rosenfeld, CS1
Bolwell, B1
LeFever, A1
Taylor, R1
List, A1
Fay, J1
Collins, R1
Andrews, F1
Pallansch, P1
Schuster, MW1
Resta, D1
Levitt, D1
Nemunaitis, J1
Bacigalupo, A1
Van Lint, MT1
Valbonesi, M1
Lercari, G1
Carlier, P1
Lamparelli, T1
Gualandi, F1
Occhini, D1
Bregante, S1
Valeriani, A1
Piaggio, G1
Pitto, A1
Benvenuto, F1
Figari, O1
De Stefano, G1
Caimo, A1
Sessarego, M1
Schiffman, KS1
Bensinger, WI1
Appelbaum, FR1
Rowley, S1
Lilleby, K1
Clift, RA1
Weaver, CH1
Sanders, JE1
Petersdorf, S1
Gooley, T1
Weiden, P1
Zuckerman, N1
Montgomery, P1
Maziarz, R1
Klarnet, JP1
Rivkin, S1
Trueblood, K1
Storb, R1
Holmberg, L1
Buckner, CD1
Ruggiero, A1
Conter, V1
Milani, M1
Biagi, E1
Lazzareschi, I1
Sparano, P1
Riccardi, R1
Bitran, JD1
Williams, SF1
Moormeier, J1
Mick, R1
Giannone, L1
Greco, FA1
Hainsworth, JD1
Prokhorova, EV1
Potopal'skiĭ, AI1
Shishka, GV1
Iordan, AM1
Moskalik, KG1
Kozlov, AP1
Akimov, AA1
Valeriote, FA1
Tolen, SJ1
Calcutt, G1
Laugier, P1
Ellena, V1
Barale, T1
Bulté, C1
Ota, K2
Kurita, S1
Nishimura, M1
Sugiyama, Y1
Ogawa, M1
Andersen, AP1
Brincker, H1

Clinical Trials (5)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Studio Osservazionale Retrospettivo Multicentrico Sull'Utilizzo di Ibrutinib in Monoterapia o in Associazione a Immunochemioterapia Secondo Schema R-CHOP in Pazienti Adulti Con Diagnosi di PCNSL Ricaduto o Refrattario[NCT05782374]36 participants (Anticipated)Observational2022-08-10Recruiting
Intensive Conditioning Regimen With Thiotepa Combined With Busulfan, Fludarabine and Cytarabine for Allogeneic Hematopoietic Stem Cell Transplantation in the Treatment of Myeloid Malignancies With Extramedullary Involvement[NCT06111612]50 participants (Anticipated)Observational2024-01-01Not yet recruiting
High-dose Chemotherapy and Autologous Stem Cell Transplant or Consolidating Conventional Chemotherapy in Primary CNS Lymphoma - Randomized Phase III Trial[NCT02531841]Phase 3250 participants (Anticipated)Interventional2014-07-31Recruiting
A Phase 2a Study of the Addition of Temozolomide to a Standard Conditioning Regimen for Autologous Stem Cell Transplantation in Relapsed and Refractory Central Nervous System (CNS) Lymphoma[NCT01235793]Phase 211 participants (Actual)Interventional2010-10-14Terminated (stopped due to The clinical trial was terminated due to poor enrollment)
Freiburg ZNS-NHL Study: Therapy for Patients With Primary Non-Hodgkin Lymphoma of the CNS - Sequential High Dosage Chemotherapy With Autologous Peripheral Blood Stem Cell Plantation[NCT00647049]Phase 278 participants (Anticipated)Interventional2007-01-31Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Safest Dose of Temozolomide for the DRBEAT Regimen

Safety will be assessed using a dose escalation design for temozolomide's use to determine the target dose and also to evaluate any and all acute treatment related toxicities. During the course of patient follow up and therapy, toxicities will be evaluated, particularly as the investigators will be determining the target dose of temozolomide. One of the major criteria for dose limiting toxicity for the study will be any Grade 3 or 4 nonhematologic toxicity from a list of commonly expected toxicities associated with autologous transplantation and temozolomide. (NCT01235793)
Timeframe: One Year

Interventiondose in mg/m^2 (Number)
DRBEAT Regimen773.25

One-year Progression-free Survival and Overall Survival

"Efficacy of the DRBEAT Regimen will be assessed by analysis of~one-year progression-free survival (PFS), defined as the time interval from maximal response from therapy to tumor regrowth, progression*, or death, (*Progression is defined as meeting the response criteria listed in Table 4: Response Criteria for Primary Central Nervous System Lymphoma according to Abrey LE, Batchelor TT, Ferreri AJM et al.)~and~Overall survival, defined as the time interval between the date of transplant and the date of death from any cause." (NCT01235793)
Timeframe: (1) One Year (2) Until date of death from any cause, assessed up to 2 years

InterventionDays (Median)
Progression Free SurvivalOverall Survival
DRBEAT Regimen132564

Reviews

7 reviews available for thiotepa and Germinoblastoma

ArticleYear
Therapy of primary CNS lymphoma: role of intensity, radiation, and novel agents.
    Hematology. American Society of Hematology. Education Program, 2017, 12-08, Volume: 2017, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Autografts; Blood-Brain Barrier; Central Nervous Sys

2017
Effectiveness and safety of thiotepa as conditioning treatment prior to stem cell transplant in patients with central nervous system lymphoma.
    Leukemia & lymphoma, 2014, Volume: 55, Issue:12

    Topics: Central Nervous System Neoplasms; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Tran

2014
Management of leptomeningeal malignancy.
    Expert opinion on pharmacotherapy, 2005, Volume: 6, Issue:7

    Topics: Adenocarcinoma; Algorithms; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Arac

2005
Lymphoma in the older patient.
    Seminars in oncology, 1995, Volume: 22, Issue:1 Suppl 1

    Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Humans;

1995
Intrathecal chemotherapy with antineoplastic agents in children.
    Paediatric drugs, 2001, Volume: 3, Issue:4

    Topics: Adrenal Cortex Hormones; Antineoplastic Agents; Blood-Brain Barrier; Cerebellar Neoplasms; Cerebrosp

2001
[Use of optical quantum generators (lasers) in oncology].
    Voprosy onkologii, 1972, Volume: 18, Issue:8

    Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Bronchial Neoplasms; Carcinoma, Basal Cell; Carcinom

1972
Multiple combination therapy in cancer chemotherapy in Japan.
    Gan, 1969, Volume: 60, Issue:3

    Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Chloroquine; Cyclophosphamide; Cytarabine; Drug

1969

Trials

17 trials available for thiotepa and Germinoblastoma

ArticleYear
Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial.
    Leukemia, 2022, Volume: 36, Issue:7

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Combined Mo

2022
Outcomes of Consecutively Diagnosed Primary Central Nervous System Lymphoma Patients Using the Alberta Lymphoma Clinical Practice Guideline Incorporating Thiotepa-Busulfan Conditioning for Transplantation-Eligible Patients.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2019, Volume: 25, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Alberta; Autografts; Busulfan; Central Nervous System Neoplasms; Dis

2019
Clinical relevance of the dose of cytarabine in the upfront treatment of primary CNS lymphomas with methotrexate-cytarabine combination.
    The oncologist, 2011, Volume: 16, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Combi

2011
Intensive chemotherapy with thiotepa, busulfan and cyclophosphamide and hematopoietic stem cell rescue in relapsed or refractory primary central nervous system lymphoma and intraocular lymphoma: a retrospective study of 79 cases.
    Haematologica, 2012, Volume: 97, Issue:11

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Central Nervous System Neopla

2012
Chemoradiotherapy for primary CNS lymphoma: an intent-to-treat analysis with complete follow-up.
    Neurology, 2005, Jan-11, Volume: 64, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain; Central Nervous System Neoplasms

2005
High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Aug-20, Volume: 24, Issue:24

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Central Nervous System Neoplasms;

2006
High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Aug-20, Volume: 24, Issue:24

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Central Nervous System Neoplasms;

2006
High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Aug-20, Volume: 24, Issue:24

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Central Nervous System Neoplasms;

2006
High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Aug-20, Volume: 24, Issue:24

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Central Nervous System Neoplasms;

2006
Primary central nervous system lymphoma treated with high-dose methotrexate, high-dose busulfan/thiotepa, autologous stem-cell transplantation and response-adapted whole-brain radiotherapy: results of the multicenter Ostdeutsche Studiengruppe Hamato-Onkol
    Annals of oncology : official journal of the European Society for Medical Oncology, 2007, Volume: 18, Issue:4

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Central Nervous S

2007
A fludarabine, thiotepa reduced toxicity conditioning regimen designed specifically for allogeneic second haematopoietic cell transplantation after failure of previous autologous or allogeneic transplantation.
    Bone marrow transplantation, 2008, Volume: 41, Issue:10

    Topics: Adult; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neo

2008
Dosing of thioTEPA for myeloablative therapy.
    Cancer chemotherapy and pharmacology, 1995, Volume: 37, Issue:1-2

    Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Bone Marrow; Bone Marrow Transplantation; Fema

1995
A phase I-II study of high-dose thiotepa, busulfan and cyclophosphamide as a preparative regimen for autologous transplantation for malignant lymphoma.
    Leukemia & lymphoma, 1995, Volume: 17, Issue:5-6

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Chemic

1995
[Lymphatic interventional radiology in the treatment of lymphatic neoplasmas].
    Zhonghua yi xue za zhi, 1995, Volume: 75, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Lymphatic M

1995
A phase I-II study of high-dose thiotepa, busulfan and cyclophosphamide as a preparative regimen for allogeneic marrow transplantation.
    Bone marrow transplantation, 1994, Volume: 14, Issue:3

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busu

1994
Chemotherapy without radiation therapy as initial treatment for primary CNS lymphoma in older patients.
    Neurology, 1996, Volume: 46, Issue:2

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cent

1996
Comparison of four cytokine regimens for mobilization of peripheral blood stem cells: IL-3 alone and combined with GM-CSF or G-CSF.
    Bone marrow transplantation, 1996, Volume: 17, Issue:2

    Topics: Adult; Bone Marrow; Breast Neoplasms; Busulfan; Carboplatin; Carmustine; Cyclophosphamide; Drug Admi

1996
Thiotepa cyclophosphamide followed by granulocyte colony-stimulating factor mobilized allogeneic peripheral blood cells in adults with advanced leukemia.
    Blood, 1996, Jul-01, Volume: 88, Issue:1

    Topics: Actuarial Analysis; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone M

1996
Phase II study of high-dose busulfan, melphalan and thiotepa with autologous peripheral blood stem cell support in patients with malignant disease.
    Bone marrow transplantation, 1996, Volume: 17, Issue:6

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Busulfan;

1996
Combination intraventricular chemotherapy for meningeal neoplasia.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1986, Volume: 4, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Cytarabi

1986

Other Studies

45 other studies available for thiotepa and Germinoblastoma

ArticleYear
Intensive chemotherapy followed by autologous stem cell transplantation in primary central nervous system lymphomas (PCNSLs). Therapeutic outcomes in real life-experience of the French Network.
    Bone marrow transplantation, 2022, Volume: 57, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Central Nervous System; Centra

2022
The role of whole-brain radiotherapy (WBRT) in primary central nervous system lymphoma: is it an alternative to ASCT for consolidation following HD-methotrexate based induction in low-income settings?
    Radiation oncology (London, England), 2022, Oct-22, Volume: 17, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Brain; Central Nervous System; Central Nervous Syste

2022
International multicenter retrospective analysis of thiotepa-based autologous stem cell transplantation for secondary central nervous system lymphoma.
    Haematologica, 2023, 03-01, Volume: 108, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Central Nervous System Neopl

2023
Methotrexate, cytarabine, thiotepa and rituximab (MATRix) chemoimmunotherapy for primary central nervous system lymphoma: a Toronto experience.
    Haematologica, 2023, 04-01, Volume: 108, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Central Nervous System Neopl

2023
Methotrexate, cytarabine, thiotepa and rituximab (MATRix) chemoimmunotherapy for primary central nervous system lymphoma: a Toronto experience.
    Haematologica, 2023, 04-01, Volume: 108, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Central Nervous System Neopl

2023
Methotrexate, cytarabine, thiotepa and rituximab (MATRix) chemoimmunotherapy for primary central nervous system lymphoma: a Toronto experience.
    Haematologica, 2023, 04-01, Volume: 108, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Central Nervous System Neopl

2023
Methotrexate, cytarabine, thiotepa and rituximab (MATRix) chemoimmunotherapy for primary central nervous system lymphoma: a Toronto experience.
    Haematologica, 2023, 04-01, Volume: 108, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Central Nervous System Neopl

2023
Thiotepa, Busulfan, Cyclophosphamide: Effective but Toxic Conditioning Regimen Prior to Autologous Hematopoietic Stem Cell Transplantation in Central Nervous System Lymphoma.
    Medical sciences (Basel, Switzerland), 2023, 01-29, Volume: 11, Issue:1

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Central Nervous System; Cyclophospha

2023
Long-Term Results with Thiotepa-Containing Conditioning Regimens for Autologous Stem Cell Transplantation.
    Transplantation and cellular therapy, 2023, Volume: 29, Issue:8

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Hematopoietic Ste

2023
Impact of Thiotepa-Based Autologous Hematopoietic Cell Transplantation in Primary Central Nervous System Lymphoma in First Complete Remission: A University of California Hematologic Malignancies Consortium Retrospective Analysis.
    Clinical lymphoma, myeloma & leukemia, 2023, Volume: 23, Issue:10

    Topics: Adult; Central Nervous System; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Human

2023
Durable Survival Outcomes in Primary and Secondary Central Nervous System Lymphoma After High-dose Chemotherapy and Autologous Stem Cell Transplantation Using a Thiotepa, Busulfan, and Cyclophosphamide Conditioning Regimen.
    Clinical lymphoma, myeloma & leukemia, 2020, Volume: 20, Issue:7

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Central Nervous System Neoplasms; Cy

2020
Secondary failure of platelet recovery in patients treated with high-dose thiotepa and busulfan followed by autologous stem cell transplantation.
    International journal of hematology, 2020, Volume: 112, Issue:5

    Topics: Adult; Aged; Busulfan; Central Nervous System Neoplasms; Female; Hematopoietic Stem Cell Transplanta

2020
Should Thiotepa-Based Regimens Be the New Transplant Conditioning Strategy for Primary Central Nervous System Lymphoma?
    JAMA oncology, 2021, 07-01, Volume: 7, Issue:7

    Topics: Busulfan; Central Nervous System; Humans; Lymphoma; Thiotepa; Transplantation Conditioning

2021
High-dose chemotherapy with thiotepa, busulfan, and cyclophosphamide and autologous stem cell transplantation for patients with primary central nervous system lymphoma in first complete remission.
    Cancer, 2017, Aug-15, Volume: 123, Issue:16

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bacterial Infections; Busulfan; Central

2017
High-dose chemotherapy with thiotepa, busulfan, and cyclophosphamide and autologous stem cell transplantation for pediatric primary central nervous system lymphoma in first complete remission.
    Cancer, 2017, 07-15, Volume: 123, Issue:14

    Topics: Busulfan; Child; Cyclophosphamide; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Thiote

2017
Distinctive Infectious Complications in Patients with Central Nervous System Lymphoma Undergoing Thiotepa, Busulfan, and Cyclophosphamide-conditioned Autologous Stem Cell Transplantation.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2018, Volume: 24, Issue:9

    Topics: Busulfan; Central Nervous System Neoplasms; Cyclophosphamide; Female; Humans; Lymphoma; Male; Middle

2018
Thiotepa, busulfan, and cyclophosphamide or busulfan, cyclophosphamide, and etoposide high-dose chemotherapy followed by autologous stem cell transplantation for consolidation of primary central nervous system lymphoma.
    Annals of hematology, 2019, Volume: 98, Issue:7

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Autografts; Busulfan; Central Nervous System N

2019
MATILDE chemotherapy regimen for primary CNS lymphoma: results at a median follow-up of 12 years.
    Neurology, 2014, Apr-15, Volume: 82, Issue:15

    Topics: Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Combined Modality

2014
Severe infections after single umbilical cord blood transplantation in adults with or without the co-infusion of CD34+ cells from a third-party donor: results of a multicenter study from the Grupo Español de Trasplante Hematopoyético (GETH).
    Transplant infectious disease : an official journal of the Transplantation Society, 2015, Volume: 17, Issue:2

    Topics: Adolescent; Adult; Antigens, CD34; Bacterial Infections; Busulfan; Cohort Studies; Cord Blood Stem C

2015
Treatment of patients with secondary central nervous system lymphoma with high-dose busulfan/thiotepa-based conditioning and autologous stem cell transplant.
    Leukemia & lymphoma, 2016, Volume: 57, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Busulfan; Central Nervous System Neoplasms; Combined

2016
High pre-transplant serum ferritin and busulfan-thiotepa conditioning regimen as risk factors for hepatic sinusoidal obstructive syndrome after autologous stem cell transplantation in patients with malignant lymphoma.
    Leukemia & lymphoma, 2016, Volume: 57, Issue:1

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Female; Ferritins

2016
High-dose thiotepa-based conditioning regimens for relapsed lymphoma involving the central nervous system: from "orphan drug" to a standard-of-care?
    Leukemia & lymphoma, 2016, Volume: 57, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Humans; Lymphoma;

2016
Thiotepa-based high-dose therapy for autologous stem cell transplantation in lymphoma: a retrospective study from the EBMT.
    Bone marrow transplantation, 2016, Volume: 51, Issue:2

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Autografts; Carmustine; Cyt

2016
A Comprehensive Assessment of Toxicities in Patients with Central Nervous System Lymphoma Undergoing Autologous Stem Cell Transplantation Using Thiotepa, Busulfan, and Cyclophosphamide Conditioning.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2017, Volume: 23, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Central Nervous System Neopla

2017
Psychosexual development and satisfaction in long-term survivors of childhood cancer: Neurotoxic treatment intensity as a risk indicator.
    Cancer, 2017, 05-15, Volume: 123, Issue:10

    Topics: Adult; Antineoplastic Agents; Brain Neoplasms; Case-Control Studies; Cranial Irradiation; Cytarabine

2017
Platine and cytarabine-based salvage treatment for primary central nervous system lymphoma.
    Journal of neuro-oncology, 2011, Volume: 105, Issue:2

    Topics: Adult; Aged; Anti-Inflammatory Agents; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combin

2011
Prognosis after high-dose chemotherapy followed by autologous stem-cell transplantation as first-line treatment in primary CNS lymphoma--a long-term follow-up study.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Volume: 23, Issue:10

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Central Nervous System Neop

2012
High-dose thiotepa, busulfan, cyclophosphamide and ASCT without whole-brain radiotherapy for poor prognosis primary CNS lymphoma.
    Bone marrow transplantation, 2003, Volume: 31, Issue:8

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain; Brain Neoplasms; Busulfan;

2003
[Triethylenethiophosphoramide in the treatment of the osteosarcoma and lymphomatosis].
    Gan, 1956, Volume: 47, Issue:3-4

    Topics: Antineoplastic Agents; Bone Neoplasms; Humans; Lymphoma; Neoplasms; Osteosarcoma; Thiotepa

1956
[On the medical therapy of malignant lymphoma].
    Naika. Internal medicine, 1962, Volume: 10

    Topics: Antineoplastic Agents; Azaguanine; Cortisone; Cyclophosphamide; Humans; Lymphoma; Mercaptopurine; Mi

1962
[EXPERIMENTAL STUDIES ON THE ANTITUMOR EFFECT OF OLIVOMYCIN IN ASSOCIATION WITH SOME SYNTHETIC CYTOSTATIC PREPARATIONS].
    Antibiotiki, 1963, Volume: 8

    Topics: Animals; Anti-Bacterial Agents; Antibiotics, Antitubercular; Antineoplastic Agents; Busulfan; Cytost

1963
[TEST OF THE ACTION OF SOME NITROGEN MUSTARD DERIVATIVES ON STICKER'S LYMPHOSARCOMA].
    Revista brasileira de cirurgia, 1963, Volume: 46

    Topics: Animals; Cyclophosphamide; Dogs; Lymphoma; Lymphoma, Non-Hodgkin; Mechlorethamine; Neoplasms; Neopla

1963
[CURRENT PRACTICE IN THE TREATMENT OF TUMORS WITH INTRA-ARTERIAL INJECTIONS OF ANTINEOPLASTIC SUBSTANCES].
    Minerva medica, 1963, Nov-03, Volume: 54

    Topics: Aminopterin; Antineoplastic Agents; Carcinoma; Chemotherapy, Cancer, Regional Perfusion; Chlorambuci

1963
THE INTRALYMPHATIC ADMINISTRATION OF RADIOACTIVE ISOTOPES AND CANCER CHEMOTHERAPEUTIC DRUGS.
    Surgery, 1964, Volume: 55

    Topics: Abdominal Neoplasms; Angiography; Breast Neoplasms; Geriatrics; Gold; Humans; Injections; Iodine Iso

1964
ANTITUMOROUS SUBSTANCES WITH RADIOMIMETIC AND RADIOPROTECTIVE GROUPS.
    Acta - Unio Internationalis Contra Cancrum, 1964, Volume: 20

    Topics: Acetylcholine; Antineoplastic Agents; Blood Pressure; Carcinoma 256, Walker; Cats; Erythropoiesis; L

1964
EXPERIMENTAL STUDY OF OLIVOMYCIN, AN ANTITUMOUR ANTIBIOTIC.
    Acta - Unio Internationalis Contra Cancrum, 1964, Volume: 20

    Topics: Animals; Anti-Bacterial Agents; Antibiotics, Antineoplastic; Antineoplastic Agents; Busulfan; Carcin

1964
MULTIPLE TRACHEOBRONCHIAL MELANOMAS WITH TEN-YEAR SURVIVAL.
    JAMA, 1965, May-24, Volume: 192

    Topics: Bronchial Neoplasms; Cheek; Cobalt Isotopes; Drug Therapy; Head and Neck Neoplasms; Lymphedema; Lymp

1965
High-dose thiotepa, melphalan and carboplatin (TMCb) followed by autologous peripheral blood stem cell transplantation in patients with lymphoma -- a retrospective evaluation.
    Bone marrow transplantation, 2004, Volume: 34, Issue:9

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Th

2004
Leptomeningeal lymphoma: perspectives on management.
    Cancer treatment reviews, 1981, Volume: 8, Issue:2

    Topics: Antineoplastic Agents; Arachnoid; Cytarabine; Humans; Injections, Spinal; Lymphoma; Meningeal Neopla

1981
Current position of vinorelbine in cancer chemotherapy.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1995, Volume: 6, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Ci

1995
High-dose combination chemotherapy with thiotepa and autologous hematopoietic stem cell reinfusion in the treatment of patients with relapsed refractory lymphomas.
    Seminars in oncology, 1990, Volume: 17, Issue:1 Suppl 3

    Topics: Adult; Combined Modality Therapy; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease;

1990
[Isolation and study of a strain of Fisher lymphadenosis (L-5178) resistant to actinomycin (aurantin)].
    Antibiotiki, 1973, Volume: 18, Issue:4

    Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Cell Line; Cyclophosphamide; Flavonoids

1973
[Antitumor action of berberinol thiophosphamide in experimental tumors in mice].
    Voprosy onkologii, 1974, Volume: 20, Issue:4

    Topics: Adenocarcinoma; Animals; Body Weight; Carcinoma, Ehrlich Tumor; Dose-Response Relationship, Drug; Fe

1974
Survival of hematopoietic and lymphoma colony-forming cells in vivo following the administration of a variety of alkylating agents.
    Cancer research, 1972, Volume: 32, Issue:3

    Topics: Alkylating Agents; Animals; Cell Line; Cell Survival; Chlorambucil; Clone Cells; Cyclophosphamide; F

1972
Enhanced growth of transplanted tumours after treatment with cytotoxic agents.
    Biochemical pharmacology, 1968, Volume: 17, Issue:8

    Topics: Animals; Antineoplastic Agents; Busulfan; Chlorambucil; Ethers, Cyclic; Lymphoma; Mannomustine; Meth

1968
[Malignant reticulosis].
    Bulletin de la Societe francaise de dermatologie et de syphiligraphie, 1968, Volume: 75, Issue:1

    Topics: Adrenal Cortex Hormones; Aged; Humans; Lymphatic Diseases; Lymphoma; Thiotepa

1968
[Combined therapy of multiple antibiotics for malignant tumors (METT-therapy)].
    Saishin igaku. Modern medicine, 1968, Mar-10, Volume: 23, Issue:3

    Topics: Adult; Aged; Antibiotics, Antineoplastic; Cyclophosphamide; Drug Synergism; Female; Humans; Lung Neo

1968
Intracavitary thiotepa in malignant pleural and peritoneal effusions.
    Acta radiologica: therapy, physics, biology, 1968, Volume: 7, Issue:5

    Topics: Adult; Aged; Breast Neoplasms; Child; Exudates and Transudates; Female; Follow-Up Studies; Gastroint

1968